|
|---|
|
|
|
|
|
t**u
发帖数: 1572 | 1 我本来准备买 2000股 ANX @ LIMIT 2.30 price,
ANX价格在最后一分钟降到了2.30, 结果卖给我900股,
所以还有 1100股没有交易,
不知道明天ANX是升还是跌, 要不要取消没有完成的交易. | y*****l
发帖数: 5997 | 2 你设的买单挺好的，2.29小底，下面2.2有支撑。
如果明天大盘跌得不多，ANX会涨。
九月有FDA。
Drug/indication: ANX-530 (exelbine) for non-small cell lung cancer
Approval decision date: Sept. 1, 2011
ANX-530 is a reformulation of the generic chemotherapy drug vinorelbine. The
FDA issued a refuse-to-file letter for ANX-530 in 2010. | y*****l
发帖数: 5997 | 3 我是从TA说得，这个药老牛不看好。想玩Pre-FDA的话，你最好问问生物专家。 | y*****l
发帖数: 5997 | 4 新人多看看置顶的帖子。老牛是keepbuying，专门玩生拉的。ANX如果FDA通过，至少3.
4，不过的话可能到2块。我是看图说话，欢迎生物鱼和嘉斯汀补充。 | t**u
发帖数: 1572 | 5 haha, I am long ANX-530. The result of ANX-530 is itself positive, the
safety of the generic formulation is better than the original drug. The FDA
refusal to file of ANX-530 in 2010 was because of CMC issues. It was
resolved. There is issue with another generic drug (ANX-514).
3.
【在 y*****l 的大作中提到】
: 新人多看看置顶的帖子。老牛是keepbuying，专门玩生拉的。ANX如果FDA通过，至少3.
: 4，不过的话可能到2块。我是看图说话，欢迎生物鱼和嘉斯汀补充。
| y*****l
发帖数: 5997 | 6 好像射天狼也是ANX专家，如果FDA能过的话，潜力巨大。
http://seekingalpha.com/article/267816-adventrx-poised-for-run-
Adventrx Pharmaceuticals (ANX) is a specialty pharma company developing two
novel formulations of anti-cancer drugs that are designed to result in less
side effects in addition to a compound in late-stage clinical development
for the treatment of a blood disorder known as sickle cell anemia.
On 3/10/11, ANX reported its 4Q10 and full-year 2010 financial results,
including:
As of 3/1/11, had 23.7 million shares of common stock outstanding.
Loss from operations = ($8.5M) in 2010 vs. ($11.3M) in 2009; R&D
expenses in 2010 = ($3.7M) vs. ($6.5M) in 2009.
Expects to reach agreements with the FDA on Phase 3 clinical trials for
both ANX-514 and purified poloxamer 188 over the next year.
At year-end 2010, cash balance = $28M plus $21M net proceeds from equity
financing in JAN 2011 => $49M cash and no debt.
In January 2011, sold 8.2M units to RA Capital Management and other
institutional investors at $2.75 per unit, which includes one share of
common stock plus a Series A & B warrant. Series A warrants are exercisable
for up to 2.05M shares of common stock at $2.75 for up to one year of the
initial exercise date. Series B warrants are exercisable for up to 2.05M
shares of common stock at $2.75 for up to five years of the initial exercise
date.
On 4/11/11, ANX announced the completion of its acquisition of SynthRx, Inc.
which has a lead product candidate in the development (poloxamer 188) of a
treatment of the blood disorder sickle cell crisis in children, which
represents on Orphan Drug indication. ANX issued 2.8M shares of common stock
to SynthRx shareholders in addition to future milestone-based share
issuance or equivalent cash payments based on successful clinical
development and regulatory events.
Below is a summary of the pending FDA decision and planned Phase 3 clinical
trials for ANX.
1.) EXELBINE (ANX-530) (vinorelbine injectable emulsion) (novel anti-cancer
formulation): Formulated to reduce the high incidence of injection site
reactions associated with NAVELBINE while achieving similar effects in the
body (pharmacokinetic profile – absorption, distribution, metabolism, and
excretion characteristics) plus anti-cancer effect. Potential for premium
pricing compared to generic, standard formulations of this anti-cancer drug.
FDA Decision - NDA 505(b)(2)
On 1/6/11, the company announced that the FDA accepted NDA for full review
with PDUFA decision date of 9/1/11 for expected decision under a standard 10
-month review, seeking approval for same indication as NAVELBINE (
vinorelbine) including non-small cell lung cancer.
2.) ANX-514 - Docetaxel emulsion for injection (polysorbate 80/detergent-
free formulation designed to decrease incidence of potential
hypersensitivity and other adverse reactions associated with the use of
detergents in standard formulations).
Pending pivotal clinical trial to support NDA 505(b)(2) new filing.
On 2/15/11, the company announced a single additional clinical trial
required to support its NDA 505(b)(2) filing as novel formulation of chemo
drug TAXOTERE, and provided guidance on 3/10/11 to reach agreement on the
Phase 3 trial with the FDA over the next 12 months (1Q12 estimate).
3.) Poloxamer 188
On 3/10/11, the company provided guidance to reach agreement on the Phase 3
trial with the FDA over the next 12 months (1Q12 estimate), and acquired
along with SynthRx plans to conduct a trial for sickle cell crisis in
pediatric population (an Orphan Drug indication).
Shares of ANX previously reached the $3 level around the time of the company
’s NDA resubmission, and I think the stock could trade within the $4-5
range on a run-up basis going into the 9/1/11 FDA decision date, which would
value the company at approximately $100M after subtracting for the cash
balance.
While questions remain over the market potential, commercialization strategy
and ability to obtain premium pricing for EXELBINE; the pending FDA
decision and the low share count / price results in a high probability of a
stock price run-up going into a strong, reliable catalyst in the form of a
FDA decision.
Disclosure: I am long ANX.
FDA
【在 t**u 的大作中提到】
: haha, I am long ANX-530. The result of ANX-530 is itself positive, the
: safety of the generic formulation is better than the original drug. The FDA
: refusal to file of ANX-530 in 2010 was because of CMC issues. It was
: resolved. There is issue with another generic drug (ANX-514).
:
: 3.
| J********e
发帖数: 341 | 7 我不觉得这个market会有多大。Pre FDA也run了。
但是盘子小，股票少，很容易上上下下。我觉得如果哪天放量上涨了，追涨比较好。
如果有人要赌FDA结果，另外一回事。
before-fda-decision?source=yahoo
two
less
development
【在 y*****l 的大作中提到】
: 好像射天狼也是ANX专家，如果FDA能过的话，潜力巨大。
: http://seekingalpha.com/article/267816-adventrx-poised-for-run-
: Adventrx Pharmaceuticals (ANX) is a specialty pharma company developing two
: novel formulations of anti-cancer drugs that are designed to result in less
: side effects in addition to a compound in late-stage clinical development
: for the treatment of a blood disorder known as sickle cell anemia.
: On 3/10/11, ANX reported its 4Q10 and full-year 2010 financial results,
: including:
: As of 3/1/11, had 23.7 million shares of common stock outstanding.
: Loss from operations = ($8.5M) in 2010 vs. ($11.3M) in 2009; R&D
| f**********g
发帖数: 2252 | | t**u
发帖数: 1572 | 9 没前途, 才 15%, 除非有大量资金
【在 f**********g 的大作中提到】
: Up today
| f**********g
发帖数: 2252 | 10 3.8
http://finviz.com/screener.ashx?v=341&t=ANX
Form 8-K for ADVENTRX PHARMACEUTICALS INC
----------------------------------------------------------------------------
----
8-Jul-2011
Change in Directors or Principal Officers, Financial Statements and
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On July 6, 2011, the Compensation Committee (the "Committee") of the Board
of Directors (the "Board") of ADVENTRX Pharmaceuticals, Inc. (the "Company")
adopted a 2011 Mid-Year Executive Incentive Plan (the "2011 Incentive Plan"
) for the Company's officers, including its named executive officers (as
identified in the Company's proxy statement relating to the Company's 2011
annual meeting of stockholders) (the "NEOs") for the period beginning July 1
, 2011 and ending December 31, 2011 (including target awards for the NEOs
and corporate performance objectives). The 2011 Incentive Plan will be
governed and administered by the Committee.
Pursuant to the 2011 Incentive Plan, participants are eligible for incentive
awards based on the achievement of near-term corporate objectives by the
Company. Awards under the 2011 Incentive Plan generally will be paid in cash
; however, the Committee has discretion to determine the composition of each
award payment. The potential award for each of the NEOs will be based 100%
on the Company's achievement of corporate objectives and the target award
amount for each NEO is $187,500. The target amount reflects the Committee's
determination of appropriate near-term incentive compensation where
performance met objectives or was acceptable in view of prevailing
conditions. The actual payout amount of an incentive award may exceed the
target amount if performance exceeded objectives or was excellent in view of
prevailing conditions or may be less than the target amount if performance
partially met objectives or was less than acceptable. In evaluating
performance, the Committee will consider the achievement of objectives, the
degree to which performance exceeded the objective or an objective is
partially achieved, the quality of achievement, the difficulty in achieving
the objective, conditions that affected the ability to achieve objectives
and such other factors as the Committee determines are appropriate to
consider.
Payment of any awards under the 2011 Incentive Plan will be made in a single
sum on or after January 1, 2012 and on or before March 14, 2012. An NEO has
not earned and does not have any right or entitlement to any award under
the 2011 Incentive Plan until the time the award is actually paid to such
NEO. However, subject to any contractual obligations the Company may owe an
NEO, if an NEO's employment with the Company terminates prior to the payment
of an award, it will be at the sole discretion of the Committee whether or
not any award payment is made to that NEO.
The corporate performance goals under the 2011 Incentive Plan were set by
the Committee based on recommendations from the NEOs and reflect the
Committee's assessment, as of July 6, 2011, of near-term corporate
objectives the achievement of which will enhance stockholder value. The
corporate objectives involve progress with the clinical development of one
or more of the Company's product candidates, including progress with
regulatory and/or manufacturing activities, favorable responses from the U.S
. Food and Drug Administration regarding one or more of the Company's
product candidates, progress with evaluating and/or the acquisition of
additional technologies, product candidates, products and/or companies and
maintaining specified levels of capital.
Under the 2011 Incentive Plan, if a corporate objective becomes irrelevant
or undesirable during the plan period or if a strategic change affects (one
or more) objectives then, for each such affected objective, the Committee,
after considering the recommendations of the NEOs, may (i) if corporate
objectives are weighted, adjust the weightings of one or more existing
objectives, (ii) substitute one or more new objectives, if corporate
objectives are weighted, with appropriate weightings for new and existing
objectives, (iii) eliminate one or more existing objectives and, if
corporate objectives are weighted, re-weight objectives or (iv) take no
action. In addition, subject to any contractual obligations the Company may
owe a participant, the Committee has absolute discretion to abolish the 2011
Incentive Plan at any time or to alter any terms and conditions under which
incentive awards will be paid, with or without any reason and with or
without prior notice.
The descriptions of the provisions of the terms and conditions of the 2011
Incentive Plan set forth above do not purport to be complete and are
qualified in their entirety by reference to the 2011 Incentive Plan, which
is filed herewith as Exhibit 10.1 and incorporated herein by reference. | | | y***q
发帖数: 4147 | 11 进货的位子选的好好啊
【在 t**u 的大作中提到】
: 我本来准备买 2000股 ANX @ LIMIT 2.30 price,
: ANX价格在最后一分钟降到了2.30, 结果卖给我900股,
: 所以还有 1100股没有交易,
: 不知道明天ANX是升还是跌, 要不要取消没有完成的交易.
| t**u
发帖数: 1572 | 12 其实我买了4250股, 可惜对ANX估计不足, 把LIMIT PRICE设在 2.65, 早就卖了, 亏疯
了.
【在 y***q 的大作中提到】
: 进货的位子选的好好啊
| y*****l
发帖数: 5997 | 13 我们太缺乏想象力了，还要涨。
Why Adventrx shares could surge higher: Rodman & Renshaw recently raised the
price target to $16. The company is expecting an update on its Exelbine NDA
around September, which if positive could be a huge catalyst for the shares
. If the price target of $16 is reached, investors buying now will gain over
500%.
【在 t**u 的大作中提到】
: 其实我买了4250股, 可惜对ANX估计不足, 把LIMIT PRICE设在 2.65, 早就卖了, 亏疯
: 了.
| y***q
发帖数: 4147 | 14 赚了钱就好，关键是你那个底抄的太准了
【在 t**u 的大作中提到】
: 其实我买了4250股, 可惜对ANX估计不足, 把LIMIT PRICE设在 2.65, 早就卖了, 亏疯
: 了.
| f**********g
发帖数: 2252 | 15 Dendreon and ADVENTRX Present Promising Pipelines
1 hours 36 minutes ago - Marketwire via Comtex
MarketwireCancer is projected to become the leading cause of death worldwide
this year by the World Health Organization, and has already emerged as the
most expensive disease -- costing the global economy nearly a trillion
dollars a year. With cancer drugs alone costing the United States more than
$30 million a year, it is clearly a lucrative sector for drug makers. The
Bedford Report examines the outlook for companies in the Healthcare Sector
and provides equity research on Dendreon Corporation (NASDAQ: DNDN) and
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX). Access to the full company
reports can be found at:
www.bedfordreport.com/DNDN
www.bedfordreport.com/ANX
Cancer medication is also an inherently risky sector. Earlier this year
Reuters published research from BioMed Tracker and BIO, which claims that
the cancer drug success rate is a mere 4.7 percent. Upon revealing the study
, the agency's Oncologic Drugs Advisory Committee endorsed several FDA
proposals for tightening the accelerated approval standards, recommending
that sponsors generally be required to conduct randomized trials rather than
single-arm studies, and that there be more extensive postmarketing studies
to confirm clinical benefit.
The Bedford Report releases investment research on the Healthcare Sector so
investors can stay ahead of the crowd and make the best investment decisions
to maximize their returns. Take a few minutes to register with us free at
www.bedfordreport.com and get exclusive access to our numerous analyst
reports and industry newsletters.
Dendreon Corporation engages in the discovery, development, and
commercialization of therapeutics to enhance cancer treatment options for
patients. Dendreon's first product, PROVENGE, was approved by the FDA in
April 2010. Recently, the company announced that the Centers for Medicare
and Medicaid Services (CMS) has agreed to fully reimburse Provenge.
ADVENTRX Pharmaceuticals is a development-stage specialty pharmaceutical
company focused on in-licensing, developing and commercializing product
candidates for the treatment of cancer. One of the company's lead product
candidates is Exelbine and ANX-514 -- a novel emulsion formulation of
currently marketed chemotherapy drugs.
The Bedford Report provides Market Research focused on equities that offer
growth opportunities, value, and strong potential return. We strive to
provide the most up-to-date market activities. We constantly create research
reports and newsletters for our members. The Bedford Report has not been
compensated by any of the above-mentioned publicly traded companies. The
Bedford Report is compensated by other third party organizations for
advertising services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full disclaimer
at http://www.bedfordreport.com/disclaimer.
Contact:
The Bedford Report
Email Contact
SOURCE: The Bedford Report
http://www2.marketwire.com/mw/emailprcntct?id=82FF4C0AE58A1466 |
|
|
|
|
|
|
